Skip to main content
. Author manuscript; available in PMC: 2016 Sep 1.
Published in final edited form as: Pharm Res. 2015 Apr 4;32(9):3029–3043. doi: 10.1007/s11095-015-1684-4

Figure 9.

Figure 9

Western blotting showed that the HIF-1α expression was 59.1% greater in the bumetanide-treated tumors than in the control tumors (p=0.003). The increase in this transcription factor coincides with the increase in tumor hypoxia following bumetanide administration, as seen in Figure 6.